PubMed Health treatment related to Raynaud Disease: 63
Primary Raynaud 's (Raynaud's disease) and secondary Raynaud's (Raynaud's phenomenon) have no cure. However, treatments can reduce the number and severity of Raynaud's attacks. Treatments include lifestyle changes, medicines, and, rarely, surgery . Most people who have primary Raynaud 's can manage the condition with lifestyle changes. People who have secondary Raynaud's may need medicines in addition to lifestyle changes. Rarely, they may need surgery or shots . If you have Raynaud 's and develop sores on your fingers , toes, or other parts of your body, see your doctor right away. Timely treatment can help prevent permanent damage to these areas.
Drugs for Raynaud Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 94)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cilostazol |
Approved, Investigational |
Phase 4 |
|
73963-72-1 |
2754 |
Synonyms:
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
CILOSTAZOL
Cilostazole
Cilostazolum
|
Cilostazolum [INN-Latin]
OPC-13013
OPC-13013|OPC-21|Pletal®
OPC-21
Pletaal
Pletal
|
|
2 |
|
Ethanol |
Approved |
Phase 4 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
3 |
|
Acetylcholine |
Approved, Investigational |
Phase 4 |
|
51-84-3 |
187 |
Synonyms:
[2-(ACETYLOXY)ETHYL]TRIMETHYLAZANIUM
2-(Acetyloxy)-N,N,N-trimethylethanaminium
2-ACETOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AZANIUM
Acetilcolina cusi
Acetyl choline ion
Acetylcholine
Acetylcholine bromide
Acetylcholine cation
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
ACETYLCHOLINE, ACH
Acetylcholinium: acetyl-choline
|
ACh
ACh|E1001|O-acetylcholine
Alcon brand OF acetylcholine chloride
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
E1001
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
4 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
5 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
6 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
7 |
|
Protective Agents |
|
Phase 4 |
|
|
|
8 |
|
Fibrinolytic Agents |
|
Phase 4 |
|
|
|
9 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
10 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
11 |
|
Phosphodiesterase 3 Inhibitors |
|
Phase 4 |
|
|
|
12 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
13 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
14 |
|
abobotulinumtoxinA |
|
Phase 4 |
|
|
|
Synonyms:
ABOBOTULINUMTOXINA
BONT/A
BONTOXILYSIN A
BOTOX
BOTULINUM TOXIN TYPE A
|
BOTULINUM TOXINS, TYPE A
BOTULOTOXIN A
BTX-A
ONABOTULINUMTOXINA
|
|
15 |
|
Botulinum Toxins, Type A |
|
Phase 4 |
|
|
|
16 |
|
Botulinum Toxins |
|
Phase 4 |
|
|
|
17 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
18 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
19 |
|
Nitroglycerin |
Approved, Investigational |
Phase 2, Phase 3 |
|
55-63-0 |
4510 |
Synonyms:
1,2,3-Propanetrioltrinitrate
1,2,3-Propanetrioltrinitric acid
1,2,3-Propanetriyl nitrate
1,2,3-Propanetriyl nitric acid
Anginine
C01DA02
Cellegesic
CORO-NITRO
DEPONIT 10
DEPONIT 5
DILUTED NITROGLYCERIN
Dynamite
EPINITRIL
Gilustenon
Glycerin trinitrate
Glycerin trinitric acid
Glycerol trinitrate
Glycerol trinitric acid
Glycerol, nitrate triester
Glycerol, nitric acid triester
Glyceroli trinitratis
Glyceroltrinitrat
Glyceryl trinitrate
Glyceryl trinitric acid
GLYTRIN
GONITRO
LENITRAL 7.5
Minitran
MINITRAN 10
MINITRAN 15
MINITRAN 5
NATIROSE
Natispray
NG
Nitrangin
NITRIDERM TTS
Nitro bid
Nitro dur
NITRO IV
Nitro-bid
NitroBid
Nitrocap
Nitrocard
NITROCINE
NITROCONTIN CONTINUS
Nitroderm
Nitroderm TTS
Nitro-dur
NitroDur
Nitroglicerina
|
Nitroglycerin
Nitroglycerin ointment
NITROGLYCERIN TABLETS
Nitroglycerine
Nitroglycerol
Nitroglyn
Nitrol
Nitrolan
Nitrolingual
Nitrolingual Pump Spray
NITROLINGUAL PUMPSPRAY
NITRO-MACK RET
Nitromed
NITROMIN
Nitromist
NITRONAL
Nitronet
Nitrong
Nitrong parenteral
Nitrospan
Nitrostat
NTG
PERCUTOL
Perlinganit
Propane-1,2,3-triyl trinitrate
Propane-1,2,3-triyl trinitric acid
RECTIV
Rectogesic
Susadrin
SUSCARD BUCCAL
Sustac
Sustak
Sustonit
TNG
Transderm nitro
Transderm-nitro
TRANSIDERM-NITRO 10
TRANSIDERM-NITRO 5
Tridil
Trinitrate, glyceryl
Trinitrin
TRINITRIN TABLETS
Trinitrine
Trinitroglycerin
Trinitroglycerol
Trinitrolong
TRINTEK 10
TRINTEK 15
TRINTEK 5
|
|
20 |
|
Nifedipine |
Approved |
Phase 3 |
|
21829-25-4 |
4485 |
Synonyms:
4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester
4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Adalat
Adalat 10
Adalat 20
Adalat 5
ADALAT A.R.
ADALAT CC
Adalat CR
Adalat Crono
Adalat Ft
Adalat Gits
Adalat Gits 30
ADALAT IC
Adalat LA
ADALAT LA 20
ADALAT LA 30
ADALAT LA 60
Adalat LP
Adalat Oros
Adalat PA
ADALAT RET
Adalat Retard
Adalat®|BAY-A-1040|Procardia®
Adalate
ADALATE LP
ADANIF XL
Adapine
Adapress
Adcock ingram brand OF nifedipine
ADIPINE
ADIPINE MR 10
ADIPINE MR 20
ADIPINE XL
Afeditab CR
Alat
Aldipin
Alfadal
Alonix
Alonix S
Alpha-Nifedipine Retard
ANGIOPINE 10
ANGIOPINE 40 LA
ANGIOPINE 5
ANGIOPINE MR 10
ANGIOPINE MR 20
Angipec
Anifed
Anpine
Apo-Nifed
Aprical
AWD pharma brand OF nifedipine
BAY a 1040
BAY-a-1040
Bayer brand OF nifedipine
Bonacid
CALANIF
CALCHAN MR 10
CALCHAN MR 20
Calcibloc
Calcigard
CALCILAT
Camont
Cardifen
Cardilat
CARDILATE MR
Cardionorm
Chronadalate
Chronadalate Lp
Citilat
Coracten
CORACTEN SR
CORACTEN XL
Coral
Cordafen
Cordaflex
Cordalat
Cordicant
Cordilan
Cordipin
Cordipine
Corinfar
CORODAY MR
Corotrend
Corynphar
Depin
Dignokonstant
Dilafed
Dilcor
Dipinkor
Duranifin
Ecodipi
Ecodipin
Ecodipin E
|
Fedcor
Fedcor Retard
Fenamon
Fenamon Sr
Fenigidin
Fenihidin
Fenihidine
FORTIPINE LA40
GENALAT 10 RET
GENALAT 20 RET
Glopir
Hadipin
Hexadilat
HYPOLAR RET 10
HYPOLAR RET 20
HYPOLAR XL 30
Introcar
KENTIPINE
KENTIPINE MR 10
KENTIPINE MR 20
Kordafen
Korinfar
KRKA brand OF nifedipine
Macorel
Megalat
Monohydrochloride, nifedipine
Myogard
N1fedilat
Nedipin
NEOZIPINE XL
Nicardia
Nifangin
Nifar
Nifdemin
Nifebene
Nifecard
Nifecor
Nifedepat
Nifedicor
Nifedin
Nifedine
NIFEDIPINE
Nifedipine bayer brand
Nifedipine gtis
Nifedipine krka brand
Nifedipine monohydrochloride
Nifedipine orion brand
Nifedipine pfizer brand
Nifedipine Retard
Nifedipine-gtis
Nifedipino
Nifedipinum
Nifedipres
NIFEDIPRESS MR 10
NIFEDIPRESS MR 20
Nifedirex LP
NIFEDOTARD 20 MR
Nifelan
Nifelat
Nifelat Q
Nifelate
NIFELEASE
NIFENSAR XL
NIFE-WOLFF
Nificard
Nifidine
Nifipen
NIFOPRESS MR
NIFOPRESS RET
NIMODREL MR 10
NIMODREL MR 20
NIMODREL XL
Niphedipine
NIVATEN RET
Orion brand OF nifedipine
Orix
Oxcord
Pfizer brand OF nifedipine
Pidilat
Procardia
Procardia XL
Sepamit
SLOFEDIPINE XL 30
SLOFEDIPINE XL 60
TENSIPINE MR 10
TENSIPINE MR 20
Tibricol
UNIPINE XL
VALNI 20 RET
VALNI XL
VASAD
Vascard
Zenusin
|
|
21 |
|
Sodium citrate |
Approved, Investigational |
Phase 2, Phase 3 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
22 |
|
Sildenafil |
Approved, Investigational |
Phase 2, Phase 3 |
|
139755-83-2, 171599-83-0 |
5212 135398744 |
Synonyms:
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulphonyl)-4-methylpiperazine
1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
1-{[3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-ETHOXYPHENYL]SULFONYL}-4-METHYLPIPERAZINE
5-[2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YLSULFONYL)PHENYL]-1-METHYL-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE
5-[2-ETHOXY-5-(4-METHYL-PIPERAZINE-1-SULFONYL)-PHENYL]-1-METHYL-3-PROPYL-1,6-DIHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-7-ONE
Acetildenafil
Aphrodil
Caverta
Citrate, sildenafil
Desmethyl sildenafil
Desmethylsildenafil
HIP0908
HIP-0908
Homosildenafil
Hydroxyhomosildenafil
Lactate, sildenafil
NCX 911
|
NCX-911
NIPATRA
Nitrate, sildenafil
Revatio
Sildenafil
Sildenafil citrate
Sildenafil lactate
Sildenafil nitrate
Sildenafil Viagra
Sildenafil, desmethyl
Sildenafilo
UK-92480
UK-9248010
UK-92480-10
Viagra
Viagra®
VIZARSIN
|
|
23 |
|
Tadalafil |
Approved, Investigational |
Phase 3 |
|
171596-29-5 |
110635 |
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
351, IC
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
Adcirca
Adcirca®|Cialis®|IC-351|IC351
Cialis
|
IC351
IC-351
ICOS 351
Tadalafil
Tadalafilo
Tadanafil
Zalutia
|
|
24 |
|
Nitrous oxide |
Approved, Vet_approved |
Phase 3 |
|
10024-97-2 |
948 |
Synonyms:
Diazyne 1-oxide
Dinitrogen monoxide
Dinitrogen oxide
Distickstoffmonoxid
e942
Factitious air
FEMA 2779
Gas, laughing
Gaz hilarant
Hyponitrous acid anhydride
Lachgas
Laughing gas
N2O
Nitral
Nitrious oxide
Nitrogen hypoxide
Nitrogen monoxide
Nitrogen oxide (N2O)
|
Nitrogen protoxide
Nitrogenium oxydulatum
Nitrous oxide
Nitrous oxide (JP15/usp)
Nitrous oxide, compressed
Nitrous oxide, jan, usan
Nitrous oxide, refrigerated liquid
Nitrous-oxide
NNO
Oxide, nitrous
oxido Nitroso
óxido nitroso
Oxidodinitrogen(N--N)
Oxyde nitreux
Protoxyde d'azote
R-744a
Stickdioxyd
Stickstoff(I)-oxid
|
|
25 |
|
Lidocaine |
Approved, Vet_approved |
Phase 3 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
26 |
|
Prilocaine |
Approved |
Phase 3 |
|
721-50-6 |
4906 |
Synonyms:
2-(Propylamino)-O-propionotoluidide
2-Methyl-alpha-propylaminopropionanilide
2-Methyl-a-propylaminopropionanilide
2-Methyl-α-propylaminopropionanilide
alpha-N-Propylamino-2-methylpropionanilide
a-N-Propylamino-2-methylpropionanilide
ASTRA 1512
Astra 1515
Astra brand OF prilocaine hydrochloride
ASTRA-1512
ASTRA-1515
AstraZeneca brand OF prilocaine hydrochloride
Citanest
Citanest octapressin
Citanest Plain
Delvet brand OF prilocaine hydrochloride
Inibsa brand OF prilocaine hydrochloride
L-67
|
N-(2-Methylphenyl)-2-(propylamino)propanamide
NSC-40027
O-Methyl-2-propylaminopropionanilide
O-Methyl-alpha-propylaminopropionanilide
O-Methyl-a-propylaminopropionanilide
O-Methyl-α-propylaminopropionanilide
Parnell brand OF prilocaine hydrochloride
PRILOCAIN
Prilocaina
PRILOCAINE
PRILOCAÏNE
Prilocaine base
Prilocaine hydrochloride
Prilocainum
PRILOTEKAL
Propitocaine
Xylonest
Α-N-propylamino-2-methylpropionanilide
|
|
27 |
|
Amlodipine |
Approved |
Phase 2, Phase 3 |
|
88150-42-9 |
2162 |
Synonyms:
(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid
Almirall brand OF amlodipine besilate
Amlocard
Amlodipine
Amlodipine Benzenesulfonate
Amlodipine besilate
Amlodipine besylate
amlodipine besylate|amlodipine maleate|Copalia® (amlodipine + valsartan)|Katerzia® (amlodipine oral suspension, 1 mg/mL)|Norvasc®|UK-4834011
Amlodipine free base
Amlodipine maleate
Amlodipine maleate (1:1)
Amlodipine, (+-)-isomer
Amlodipine, (+-)-isomer, maleate (1:1)
Amlodipine, (R)-isomer
Amlodipine, (S)-isomer, maleate (1:1)
Amlodipino
Amlodipino [Spanish]
Amlodipinum
|
Amlodipinum [Latin]
Amlodis
Amlor
AMVAZ
Astudal
ASTUDAL 5
CKD-330 COMPONENT AMLODIPINE
Coroval
Eczacibasi brand OF amlodipine besilate
HGP0904
HGP-0904
Istin
Lipinox
Lotrel
Mack brand OF amlodipine besilate
NORVAS
Norvasc
Pelmec
Pfizer brand OF amlodipine besilate
Racemic amlodipine
|
|
28 |
|
Udenafil |
Approved, Investigational |
Phase 2, Phase 3 |
|
268203-93-6 |
6918523 135413547 |
Synonyms:
3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-N-(2-(1-methyl-2-pyrrolidinyl)ethyl)-4-propoxybenzenesulfonamide
DA-8159
DA-8159|DA8159|Zydena®
|
DA-8159udenafil
UDENAFIL
Zidena
|
|
29 |
|
Clopidogrel |
Approved |
Phase 2, Phase 3 |
|
120202-66-6, 113665-84-2 |
60606 |
Synonyms:
(+)-(S)-Clopidogrel
(+)-Clopidogrel
(S)-Clopidogrel
BMS Brand 1 OF clopidogrel bisulfate
BMS Brand 2 OF clopidogrel bisulfate
CLOPIDOGREL
Clopidogrel [Ban:Inn]
Clopidogrel besilate
Clopidogrel besylate
Clopidogrel bisulfate
Clopidogrel bisulphate
Clopidogrel hydrochloride
CLOPIDOGREL HYDROGEN SULFATE
Clopidogrel mepha
Clopidogrel napadisilate
|
Clopidogrel sandoz
CLOPIDOGREL SULFATE
Clopidogrel, (+)(S)-isomer
Clopidogrel-mepha
Clopidogrelum
GREPID
Iscover
Isocover
Plavix
PLAVIX®
R 130964
R-130964
SR 25990
SR-25990
SR-25990C
|
|
30 |
|
Bupivacaine |
Approved, Investigational |
Phase 2, Phase 3 |
|
2180-92-9, 38396-39-3 |
2474 |
Synonyms:
(+-)-Bupivacaine
(±)-bupivacaine
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Abbott brand OF bupivacaine hydrochloride
ANEKAIN
Anhydrous, bupivacaine
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bloqueina
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
Bucaine
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
BUPIVACAINE
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
|
Carbonate, bupivacaine
Carbostesin
CBupivacaine
Chirocaine
DepoBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
DL-Bupivacaine|Exparel®|Marcain®|Posimir®|Sensorcaine®|W-7|Xaracoll®
Dolanaest
DUR-843
Exparel
Hydrochloride, bupivacaine
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
LAC-43
LIQ865
LIQ-865
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
Pisa brand OF bupivacaine hydrochloride
Racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SKY-0402
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
|
|
31 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2, Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
32 |
|
St. John's Wort |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
84082-80-4 |
|
Synonyms:
Common st johnswort flowering top
Common st. john's wort flowering top
Common st. john's wort herb
Common st. johnswort flowering top
Guanyejinsitao
Hyperici herba
HYPERICUM
Hypericum nachitschevanicum flowering top
Hypericum perforatum flowering top
Hypoxis hemerocallidea root extract
|
Klamath weed flowering top
Klamathweed flowering top
POWDERED ST. JOHN'S WORT EXTRACT
Saint johns wort
St john's wort
St Johns Wort
St. john’s wort
St. johns wort
ST. JOHN'S WORT
St. johnswort flowering top
|
|
33 |
|
Fasudil |
Investigational |
Phase 3 |
|
103745-39-7 |
3547 |
Synonyms:
1-(5-Isoquinolinesulfonyl)homopiperazine
5-(1,4-Diazepan-1-sulphonyl)isoquinoline
5-(1,4-Diazepane-1-sulphonyl)isoquinoline
AT 877
AT-877
dihydrochloride fasudil|HA 1077|HA1077
FASUDIL
|
Fasudil hydrochloride
Fasudil mesylate
HA 1077
HA1077
HA-1077
HA-1077at-877fasudil
ZK-258594
|
|
34 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
35 |
|
Hormones |
|
Phase 3 |
|
|
|
36 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 3 |
|
|
|
37 |
|
calcium channel blockers |
|
Phase 3 |
|
|
|
38 |
|
Citrate |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
Tocolytic Agents |
|
Phase 3 |
|
|
|
40 |
|
Antihypertensive Agents |
|
Phase 2, Phase 3 |
|
|
|
41 |
|
Protein Kinase Inhibitors |
|
Phase 3 |
|
|
|
42 |
|
Insulin, Globin Zinc |
|
Phase 3 |
|
|
|
43 |
|
Insulin |
|
Phase 3 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
44 |
|
Anticoagulants |
|
Phase 3 |
|
|
|
45 |
|
Chelating Agents |
|
Phase 3 |
|
|
|
46 |
|
Vardenafil Dihydrochloride |
|
Phase 2, Phase 3 |
|
|
|
47 |
|
Platelet Aggregation Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
48 |
|
Purinergic P2Y Receptor Antagonists |
|
Phase 2, Phase 3 |
|
|
|
49 |
|
Anesthetics, Local |
|
Phase 2, Phase 3 |
|
|
|
50 |
|
Anesthetics |
|
Phase 2, Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 78)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon |
Completed |
NCT00048776 |
Phase 4 |
Pletal |
2 |
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon |
Completed |
NCT00048763 |
Phase 4 |
Pletal |
3 |
Double Blind RCT to Evaluate the Effect of Botulinum Toxin in Raynaud Phenomenon |
Recruiting |
NCT05125029 |
Phase 4 |
Botulinum toxin |
4 |
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon, a Double-Blind Randomized Placebo-Controlled Trial |
Terminated |
NCT03639766 |
Phase 4 |
AbobotulinumtoxinA |
5 |
A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon |
Unknown status |
NCT00934427 |
Phase 3 |
0.9% nitroglycerin in TAM cream;vehicle cream |
6 |
A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon |
Unknown status |
NCT00577304 |
Phase 3 |
Nitroglycerin;Topical AmphiMatrix |
7 |
Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon |
Completed |
NCT00253331 |
Phase 2, Phase 3 |
topical organogel with nitroglycerin |
8 |
Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma |
Completed |
NCT00626665 |
Phase 3 |
Tadalafil |
9 |
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis |
Completed |
NCT00004786 |
Phase 3 |
iloprost |
10 |
Efficacy and Safety of "as Required" Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP) |
Completed |
NCT02050360 |
Phase 2, Phase 3 |
Sildenafil 40 mg;Sildenafil 80 mg;Placebo |
11 |
Efficacy, Tolerability and Biology of a Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon |
Completed |
NCT00498615 |
Phase 3 |
Fasudil |
12 |
Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon |
Completed |
NCT00419419 |
Phase 3 |
Topical AmphiMatrix with nitroglycerin (MQX-503) |
13 |
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Study to Assess Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis |
Completed |
NCT03717961 |
Phase 3 |
BOTOX® solution;Placebo group |
14 |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study) |
Completed |
NCT04040322 |
Phase 3 |
Placebo IV infusion;Iloprost Injection, for intravenous use |
15 |
A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon |
Completed |
NCT00351117 |
Phase 3 |
St. John's Wort;Lactose |
16 |
Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon |
Completed |
NCT00266669 |
Phase 3 |
Topical organogel with nitroglycerin |
17 |
Raynaud's Treatment Study (RTS) |
Completed |
NCT00000530 |
Phase 3 |
nifedipine |
18 |
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study |
Completed |
NCT01117298 |
Phase 3 |
Tadalafil;Placebo |
19 |
A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome |
Completed |
NCT02165111 |
Phase 3 |
Onabotulinumtoxin A;sterile saline solution |
20 |
Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial |
Completed |
NCT01347008 |
Phase 3 |
Sildenafil citrate;Placebo (Sugar pill) |
21 |
Double-blind, Placebo-controlled Cross-over Study to Investigate the Effects of the Phosphodiesterase 5-inhibitor Vardenafil on Periphery Blood Flow and Clinical Symptoms of Patients With Raynaud's Syndrome |
Completed |
NCT01291199 |
Phase 2, Phase 3 |
vardenafil;Placebo |
22 |
Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial |
Completed |
NCT01280266 |
Phase 2, Phase 3 |
Udenafil or Amlodipine |
23 |
Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon |
Recruiting |
NCT05098704 |
Phase 2, Phase 3 |
clopidogrel treatment;Placebo |
24 |
Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine |
Terminated |
NCT02374320 |
Phase 2, Phase 3 |
liposomal bupivacaine |
25 |
Safety and Efficacy Study of Pl-vegf165 to Treat Secondary Raynaud's Phenomenon Caused by Systemic Scleroderma |
Unknown status |
NCT02356809 |
Phase 1, Phase 2 |
Neovasculgen |
26 |
Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP) |
Completed |
NCT01926847 |
Phase 2 |
Riociguat (Adempas, BAY63-2521);Placebo |
27 |
Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon |
Completed |
NCT00251238 |
Phase 2 |
Ginkgo biloba extract EGb 761 |
28 |
Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon |
Completed |
NCT00378521 |
Phase 2 |
MQX-503 |
29 |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis |
Completed |
NCT03867097 |
Phase 2 |
Placebo IV infusion;Iloprost Injection, for intravenous use |
30 |
A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine, Vascana®, Versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects With Raynaud's Phenomenon (RP) Secondary to Connective Tissue Disease |
Completed |
NCT02688270 |
Phase 2 |
Vascana (0.9% nitroglycerin cream);Vehicle Cream (placebo) |
31 |
Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon |
Completed |
NCT00480753 |
Phase 2 |
Nitroglycerin |
32 |
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis |
Completed |
NCT02260557 |
Phase 2 |
Selexipag;Placebo |
33 |
A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc) |
Completed |
NCT04744207 |
Phase 2 |
GS-248;Placebo |
34 |
A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease. |
Completed |
NCT00528242 |
Phase 2 |
SLx-2101;Placebo |
35 |
A Phase 2, Single-center, Randomised, Double-blind, Placebo-controlled, Cross-over Cold Challenge Study Investigating the Effect of C21 on Cold-induced Vasoconstriction in Subjects With Raynaud's Phenomenon (RP) Secondary to Systemic Sclerosis (SSc) |
Completed |
NCT04388176 |
Phase 2 |
C21;Placebo |
36 |
A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon |
Completed |
NCT01090492 |
Phase 2 |
PF-00489791 |
37 |
A 28-Day Randomized, Double-Blind, Placebo-Controlled Clinical Trial and 5-Year Prospective Outcomes Study: A Two-Part Study of BOTOX® Therapy for Ischemic Digits |
Completed |
NCT01309802 |
Phase 2 |
onabotulinum toxin type-A |
38 |
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma) |
Completed |
NCT02228850 |
Phase 2 |
Alprostadil |
39 |
Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial of the Efficacy and Safety of IC351 in Female Patients With Raynaud Phenomenon and Female Sexual Dysfunction Secondary to Systemic Sclerosis |
Completed |
NCT00707187 |
Phase 2 |
Cialis |
40 |
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis |
Terminated |
NCT04915950 |
Phase 2 |
Temanogrel;Placebo |
41 |
Phase IIa Study of the Efficacy of ORM-12471 for Prevention of Cold-induced Vasospasm: a Randomised, Double-blind, Placebo-controlled, Single Centre Crossover Study in Patients With Raynaud's Phenomenon Secondary to Systemic Sclerosis |
Terminated |
NCT01315899 |
Phase 2 |
ORM-12471 30mg;ORM-12471;placebo |
42 |
MXQ-503 Applied To The Hand Vs. Nitroglycerin Ointment 2%, USP, Applied To The Chest: A Pharmacokinetic Comparison In Normal Subjects |
Completed |
NCT00841594 |
Phase 1 |
nitroglycerin 0.9 % (MXQ-503);Nitroglycerin ointment 2%, USP |
43 |
A Phase I Trial of the Pharmacodynamic Dose Response to Topical Trinitrate in Patients With Raynaud's Phenomenon |
Completed |
NCT00700518 |
Phase 1 |
placebo cream;Glyceryl Trinitrate |
44 |
Rôle Des Acides Epoxy-eicosatriénoïques et du Monoxyde d'Azote Dans l'hyperhémie Post-occlusive cutanée Digitale et la réponse cutanée au Froid Dans le phénomène de Raynaud Primaire |
Unknown status |
NCT02183779 |
|
L-NMMA and Fluconazole dermic injection |
45 |
Hit Hard and Early. The Effect of High Dose Methylprednisolone on Nailfold Capillary Changes and Biomarkers in Early SSc: a 12-week Randomised Explorative Double-blind Placebo-controlled Trial. |
Unknown status |
NCT03059979 |
Early Phase 1 |
Methylprednisolone |
46 |
Localized Effects of Photobiomodulation and Exogenous Nitric Oxide on CREST Patients Calcinosis Cutis & Raynaud Phenomenon |
Unknown status |
NCT03972566 |
|
INOMAX |
47 |
Monocenter, IIT, Open Controlled and Prospectiv Study to Define the Prognostic Influence of Light Rheography Measurement of Patients With Secundary Raynaud Syndrome With Ulcers at Fingertips Throughout the Medicinal Therapy |
Unknown status |
NCT01378845 |
|
Tracleer;Prostavasin |
48 |
RaynAUT - Thermography and the Autonomic Nervous System in Raynaud's Phenomenon - Investigation of the Autonomic Nervous System in Patients With Raynaud's Phenomenon, Glaucoma, and Autonomic Neuropathy. |
Completed |
NCT03094910 |
|
|
49 |
"Color Doppler Ultrasound Comparison of Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud: A Randomized, Double-blind, Placebo-controlled Pilot Study" |
Completed |
NCT03027674 |
Early Phase 1 |
10% nifedipine cream;5% sildenafil cream |
50 |
Effectiveness of an Intervention Program With Electric Stimulation Therapy in Patients With Raynaud's Phenomenon: a Randomized Clinical Trial |
Completed |
NCT03699436 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Captopril
Isoxsuprine
Isoxsuprine Hydrochloride
Papaverine
Papaverine Hydrochloride
|
Prazosin
Prazosin hydrochloride
Tolazoline
Tolazoline Hydrochloride
|
Cochrane evidence based reviews: raynaud disease
|